Combining SBRT and Lenalidomide for treating Solitary Plasmacytoma
A Phase II Trial of Stereotactic Body Radiotherapy (SBRT) With Lenalidomide Maintenance for Solitary Plasmacytoma
This study is testing whether combining a targeted radiation treatment with a medication can help people with a rare type of tumor called solitary plasmacytoma respond better to treatment and live longer without the disease progressing.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 41 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University Academic / other |
| Drugs / interventions | Radiation |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Trial ID | NCT06863584 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of combining Stereotactic Body Radiation Therapy (SBRT) with Lenalidomide in patients diagnosed with solitary plasmacytoma, a rare malignant plasma cell tumor. SBRT is a precision radiotherapy technique that delivers high doses of radiation to the tumor while minimizing exposure to surrounding healthy tissues, potentially improving local control and reducing side effects. The trial aims to assess the local response rates and progression-free survival of patients receiving this combined treatment approach. Eligible participants must have newly diagnosed solitary plasmacytoma and meet specific diagnostic criteria.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 80 with newly diagnosed solitary plasmacytoma confirmed by biopsy and no evidence of multiple myeloma.
Not a fit: Patients who are not suitable for radiotherapy or have a performance status score greater than 2 may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly improve local control and reduce disease progression in patients with solitary plasmacytoma.
How similar studies have performed: Previous studies have shown promising results with SBRT in similar conditions, indicating potential for success in this novel combination approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with newly diagnosed solitary plasmacytoma (SP). * Age between 18 and 80 years. * Diagnosis of SP must meet the following four criteria: Biopsy-confirmed plasmacytoma in bone or soft tissue. No evidence of clonal plasma cell proliferation in the bone marrow. No other lesions detected on whole-body imaging (whole-body PET-CT or MRI recommended) except for the primary solitary lesion. No end-organ damage caused by plasma cell disease, including SLiM CRAB \[excluding bone destruction caused by the SP itself. Exclusion Criteria: * Patients who are not suitable for radiotherapy or unable to receive SBRT due to technical limitations, such as patients with plasmacytoma in the extremities who cannot abduct the affected limb or maintain the treatment position due to pain. * Eastern Cooperative Oncology Group (ECOG) performance status score greater than 2. * Patients who meet the diagnostic criteria for multiple myeloma at the time of diagnosis: bone marrow biopsy showing more than 10% plasma cells, serum calcium level above 11.5 mg/dL, serum creatinine above 2 mg/dL, creatinine clearance rate below 40 mL/min, or hemoglobin below 10 g/dL. * Patients with uncontrolled infectious comorbidities. * Patients with other active malignancies. * Pregnant or breastfeeding patients. * Patients with a history or current pulmonary embolism. * Patients with a history of autoimmune disease, even if it is controlled. * Patients who are seropositive for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV) DNA \> 1,000 copies/mL. * Patients with myocardial infarction within 6 months prior to enrollment, New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, or severe uncontrolled arrhythmia. * Patients with neuropathy Grade 2 or higher according to the National Cancer Institute Common Terminology Criteria for Adverse Events. * Patients with neutrophil count \< 1×10\^9/L, hemoglobin \< 8 g/dL, or platelet count \< 75×10\^9/L. * Patients with severely impaired liver or kidney function: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 3 × upper limit of normal (ULN), total bilirubin \> 1.5 × ULN, or estimated glomerular filtration rate (eGFR) \< 40 mL/min.
Where this trial is running
Hangzhou, Zhejiang
- 2nd Affiliated Hospital, School of Medicine — Hangzhou, Zhejiang, China (Recruiting)
Study contacts
- Study coordinator: Ting Zhang, phD.
- Email: zezht@zju.edu.cn
- Phone: +86-571-87783521
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.